Hans van Houte - Dec 19, 2023 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Role: Chief Financial Officer
Signature: /s/ Daniel Burbach, as Attorney-in-Fact for Hans van Houte
Stock symbol: NRIX
Transactions as of: Dec 19, 2023
Transactions value $: -$109,093
Form type: 4
Date filed: 12/20/2023, 04:55 PM
Previous filing: Nov 1, 2023
Next filing: Dec 21, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NRIX	Common Stock	Sale	-$109K	-10.9K	-12.63%	$10.00	75.5K	Dec 19, 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
F2	Represents the weighted average sale price. The lowest price at which shares were sold was $10.0000 and the highest price at which shares were sold was $10.0200. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Content

This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Represents the weighted average sale price. The lowest price at which shares were sold was $10.0000 and the highest price at which shares were sold was $10.0200. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.